Beneficial effects of irisin in experimental paroxetine-induced hyperprolactinemia.
Irisin
Paroxetine
Prolactin
Testosterone
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
19
11
2021
accepted:
04
02
2022
pubmed:
1
3
2022
medline:
7
5
2022
entrez:
28
2
2022
Statut:
ppublish
Résumé
It is known that selective serotonin reuptake inhibitors (SSRIs), represent an important and effective treatment of depression and other psychological disorders, these medications can increase prolactin levels mainly through activation of the serotonergic pathway. In this study, we aimed to determine the beneficial effects of irisin on paroxetine, a SSRI, induced hyperprolectinemia and in some other reproductive hormonal changes associated with hyperprolactinemia. Thirty two male Spraque-Dawley rats were used and divided into four groups including sham-operated control (vehicle), irisin (100 ng/kg/day for 28 days with mini-osmotic pumps), paroxetine (treated with 20 mg/kg paroxetine by oral gavage), irisin and paroxetine+irisin groups (n = 8). Serum prolactin (PRL), kisspeptin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone and 5-alpha reductase levels were determined with enzyme-linked immunosorbent analysis (ELISA). In animals treated with paroxetine, PRL level increased and testosterone level decreased significantly (p < 0.05). Serum LH level was significantly increased in the group, but no significant changes were observed in the FSH, kisspeptin and 5-alpha reductase levels. Serum prolactin levels was significantly decreased in the group treated with irisin. While no significant difference was observed in kisspeptin, FSH and 5-alpha reductase levels, an increase in serum LH and testosterone levels with irisin administration (p < 0.05). In conclusion, chronic irisin exposure may reverse paroxetine-induced hyperprolactinemia. These results indicate that irisin may have the potential to be used as a therapeutic agent by primarily affecting paroxetine-induced increased prolactin and decreased testosterone levels.
Identifiants
pubmed: 35226247
doi: 10.1007/s12020-022-03010-1
pii: 10.1007/s12020-022-03010-1
doi:
Substances chimiques
Kisspeptins
0
Serotonin Uptake Inhibitors
0
Testosterone
3XMK78S47O
Paroxetine
41VRH5220H
Prolactin
9002-62-4
Luteinizing Hormone
9002-67-9
Follicle Stimulating Hormone
9002-68-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
419-425Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
R.P. Thom, J.L. Alexander, D. Baron, A. Garakani, L. Gross, J.H. Pine, R. Radhakrishnan, A. Slaby, C.R. Sumner, Selective serotonin reuptake inhibitors: How long is long enough? J. Psychiatr. Pract. 27(5), 361–371 (2021)
doi: 10.1097/PRA.0000000000000578
S. Madhusoodanan, S. Parida, C. Jimenez, Hyperprolactinemia associated with psychotropics–a review. Hum. Psychopharmacol. 25(4), 281–297 (2010)
doi: 10.1002/hup.1116
M.R. Safarinejad, Evaluation of endocrine profile and hypothalamic-pituitary-testis axis in selective serotonin reuptake inhibitor-induced male sexual dysfunction. J. Clin. Psychopharmacol. 28(4), 418–423 (2008)
doi: 10.1097/JCP.0b013e31817e6f80
D. La Torre, A. Falorni, Pharmacological causes of hyperprolactinemia. Therapeutics Clin. Risk Manag. 3(5), 929 (2007)
V. Bernard, J. Young, P. Chanson, N. Binart, New insights in prolactin: Pathological implications. Nat. Rev. Endocrinol. 11(5), 265–275 (2015)
doi: 10.1038/nrendo.2015.36
B.J. Kinon, J.A. Gilmore, H. Liu, U.M. Halbreich, Hyperprolactinemia in response to antipsychotic drugs: Characterization across comparative clinical trials. Psychoneuroendocrinology 28, 69–82 (2003)
doi: 10.1016/S0306-4530(02)00128-2
S. Bhattacharjee, R. Biswas, N. Mandal, Selective serotonin reuptake inhibitor-induced galactorrhea with hyperprolactinemia. Indian J. Psychiatry 63(6), 613–616 (2021)
doi: 10.4103/indianjpsychiatry.indianjpsychiatry_206_21
T.A. Lorenz, C.M. Meston, Exercise improves sexual function in women taking antidepressants: results from a randomized crossover trial. Depression Anxiety 31(3), 188–195 (2014)
doi: 10.1002/da.22208
P. Boström, J. Wu, M.P. Jedrychowski, A. Korde, L. Ye, J.C. Lo, K.A. Rasbach, E.A. Boström, J.H. Choi, J.Z. Long et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481(7382), 463–468 (2012)
doi: 10.1038/nature10777
J.Y. Huh, G. Panagiotou, V. Mougios, M. Brinkoetter, M.T. Vamvini, B.E. Schneider, C.S. Mantzoros, FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metab.: Clin. Exp. 61(12), 1725–1738 (2012)
doi: 10.1016/j.metabol.2012.09.002
S. Aydin, T. Kuloglu, S. Aydin, M. Kalayci, M. Yilmaz, T. Cakmak, S. Albayrak, S. Gungor, N. Colakoglu, I.H. Ozercan, A comprehensive immunohistochemical examination of the distribution of the fat-burning protein irisin in biological tissues. Peptides 61, 130–136 (2014)
doi: 10.1016/j.peptides.2014.09.014
F. Gür, S. Timurkaan, M. Yalcin, A. Girgin, B. Gençer, Tarakçı, Immunohistochemical localization of irisin in mole rats (Spalax leucodon). Biotech. Histochemistry 92(4), 245–251 (2017)
Q. Jiang, Q. Zhang, A. Lian, Y. Xu, Irisin stimulates gonadotropins gene expression in tilapia (Oreochromis niloticus) pituitary cells. Anim. Reprod. Sci. 185, 140–147 (2017)
doi: 10.1016/j.anireprosci.2017.06.018
Y. Luo, X. Qiao, Y. Ma, H. Deng, C.C. Xu, L. Xu, Irisin deletion induces a decrease in growth and fertility in mice. Reprod. Biol. Endocrinol.: RBE 19(1), 22 (2021)
doi: 10.1186/s12958-021-00702-7
Ş. Kumsar, Ö. Ciğerli, E. Hasırcı, A.F. Akay, L. Peşkircioğlu, The relationship between serum irisin levels and erectile dysfunction in diabetic men (irisin and erectile dysfunction in diabetic patients). Andrologia 53(2), e13959 (2021)
doi: 10.1111/and.13959
F. NANEES, H.I. REHAM, Role of irisin administration in modulating testicular function in adult obese albino rats. Med. J. Cairo Univ. 86(December), 4647–4655 (2018)
doi: 10.21608/mjcu.2018.65747
A. Saleh, A. Hamed, A. Elfallah, E. Amin, Assessment of insulin resistance and serum levels of irisin in patients with idiopathic infertility. Benha J. Appl. Sci. 3(1), 145–146 (2018)
doi: 10.21608/bjas.2018.191112
T.R. de Jong, T. Pattij, J.G. Veening, M.D. Waldinger, A.R. Cools, B. Olivier, Effects of chronic selective serotonin reuptake inhibitors on 8-OH-DPAT-induced facilitation of ejaculation in rats: comparison of fluvoxamine and paroxetine. Psychopharmacology 179, 509–515 (2005)
doi: 10.1007/s00213-005-2186-6
N. Ulker, A. Yardimci, N. Kaya Tektemur, O. Bulmus, S. Ozer Kaya, F. Gulcu Bulmus, G. Turk, M. Ozcan, S. Canpolat, Irisin may have a role in pubertal development and regulation of reproductive function in rats. Reprod. (Camb., Engl.) 160(2), 281–292 (2020)
doi: 10.1530/REP-20-0072
T. Reinehr, C. Elfers, N. Lass, C.L. Roth, Irisin and its relation to insulin resistance and puberty in obese children: a longitudinal analysis. J. Clin. Endocrinol. Metab. 100(5), 2123–2130 (2015)
doi: 10.1210/jc.2015-1208
M. Hernandez-Trejo, G. Garcia-Rivas, A. Torres-Quintanilla, E. Laresgoiti-Servitje, Relationship between Irisin concentration and serum cytokines in mother and newborn. PloS one 11(11), e0165229 (2016)
doi: 10.1371/journal.pone.0165229
S. Tekin, A. Beytur, Y. Erden, A. Beytur, Y. Cigremis, N. Vardi, Y. Turkoz, I. Tekedereli, S. Sandal, Effects of intracerebroventricular administration of irisin on the hypothalamus-pituitary-gonadal axis in male rats. J. Cell. Physiol. 234(6), 8815–8824 (2019)
doi: 10.1002/jcp.27541
E. Bastu, U. Zeybek, E.G. Gurevin, B.Y. Ozgor, F. Celik, N. Okumus, I. Demiral, O. Dural, C. Celik, H. Bulut, Effects of irisin and exercise on metabolic parameters and reproductive hormone levels in high-fat diet-induced obese female mice. Reprod. Sci. 25(2), 281–291 (2018)
doi: 10.1177/1933719117711264
Y. Assyov, A. Gateva, V. Karamfilova, T. Gatev, I. Nedeva, T. Velikova, Z.A. Kamenov, Impact of testosterone treatment on circulating irisin in men with late-onset hypogonadism and metabolic syndrome. Aging Male 23(5), 1381–1387 (2020)
doi: 10.1080/13685538.2020.1770721
Z. Kamenov, Y. Assyov, P. Angelova, A. Gateva, A. Tsakova, Irisin and testosterone in men with metabolic syndrome. Horm. Metab. Res. 49(10), 755–759 (2017)
doi: 10.1055/s-0043-115227
I.P. Doulamis, A. Tzani, P. Konstantopoulos, A. Daskalopoulou, T. Spinos, E. Bletsa, D. Mitsopoulou, M. Spinou, M.E. Brinia, K. Palaiopanos, Experimental hypogonadism: insulin resistance, biochemical changes and effect of testosterone substitution. J. Basic Clin. Physiol. Pharmacol. 30(3), (2019)
A.B. Csoka, A. Bahrick, O.P. Mehtonen, Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors. J. Sex. Med. 5, 227–233 (2008)
doi: 10.1111/j.1743-6109.2007.00630.x
F. Erdemir, D. Atilgan, F. Firat, F. Markoc, B.S. Parlaktas, E. Sogut, The effect of sertraline, paroxetine, fluoxetine and escitalopram on testicular tissue and oxidative stress parameters in rats. Int. Braz. J. Urol: Off. J. Braz. Soc. Urol. 40(1), 100–108 (2014)
doi: 10.1590/S1677-5538.IBJU.2014.01.15
H.N. Bataineh, T. Daradka, Effects of long-term use of fluoxetine on fertility parameters in adult male rats. Neuro Endocrinol. Lett. 28(3), 321–325 (2007)
pubmed: 17627270
C. Tanrikut, A.S. Feldman, M. Altemus, D.A. Paduch, P.N. Schlegel, Adverse effect of paroxetine on sperm. Fertil. Steril. 94(3), 1021–1026 (2010)
doi: 10.1016/j.fertnstert.2009.04.039
O. Atli, M. Baysal, G. Aydogan-Kilic, V. Kilic, S. Ucarcan, B. Karaduman, S. Ilgin, Sertraline-induced reproductive toxicity in male rats: Evaluation of possible underlying mechanisms. Asian J. Androl. 19(6), 672 (2017)
doi: 10.4103/1008-682X.192637
S. Bell, M. Shipman, A. Bystritsky, T. Haifley, Fluoxetine treatment and testosterone levels. Ann. Clin. Psychiatry.: Off. J. Am. Acad. Clin. Psychiatrists 18(1), 19–22 (2006).
doi: 10.1080/10401230500464612
K. Wada, L. Hu, N. Mores, C.E. Navarro, H. Fuda, L.Z. Krsmanovic, K.J. Catt, Serotonin (5-HT) receptor subtypes mediate specific modes of 5-HT-induced signaling and regulation of neurosecretion in gonadotropin-releasing hormone neurons. Mol. Endocrinol. 20(1), 125–135 (2006)
doi: 10.1210/me.2005-0109
C. Sonigo, J. Bouilly, N. Carré, V. Tolle, A. Caraty, J. Tello, F.J. Simony-Conesa, R. Millar, J. Young, N. Binart, Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. J. Clin. Investig. 122(10), 3791–3795 (2012)
doi: 10.1172/JCI63937
R.S. Brown, A.E. Herbison, D.R. Grattan, Prolactin regulation of kisspeptin neurones in the mouse brain and its role in the lactation-induced suppression of kisspeptin expression. J. Neuroendocrinol. 26(12), 898–908 (2014)
doi: 10.1111/jne.12223
R.P. Millar, C. Sonigo, R.A. Anderson, J. George, L. Maione, S. Brailly-Tabard, P. Chanson, N. Binart, J. Young, Hypothalamic-pituitary-ovarian axis reactivation by kisspeptin-10 in hyperprolactinemic women with chronic amenorrhea. J. Endocr. Soc. 1(11), 1362–1371 (2017)
doi: 10.1210/js.2017-00328
N. Ulker, A. Yardimci, E. Coban, M. Ozcan, S. Canpolat, Chronic irisin exposure decreases sexual incentive motivation in female rats. Physiol. Behav. 232, 113341 (2021)
doi: 10.1016/j.physbeh.2021.113341